United States · 
What does Great Point Partners invest in?
Great Point Partners invests most often at Venture and Series A (88% of the rounds on record), in sectors such as Medical Device, In Vitro Diagnostics and Health.
Great Point Partners highlights
- 01
17 rounds on record
- 02
Mostly Venture and Series A: 88% of its rounds
- 03
Sole investor in 5 rounds, median $10M
- 04
5 exits from the portfolio
What they do
lower middle market growth buyout funds investing in private health care companiesFrom their own website
- Type
- Private equity (from a list, unverified)
- Cheque size
- Not stated
- Stages
- SeedSeries ASeries B
- Sectors
- Medical DeviceIn Vitro DiagnosticsHealth
- Based in
- Harrison, United States
- Cold pitches
- Not stated
The record
Every round we can evidence, newest first17 appearances
- 2018
1 round
- Aug
- 2014
1 round
- Feb
- 2013
4 rounds
- Dec
- Nov
- Nov
- Jun
- 2012
1 round
- Aug
- 2011
2 rounds
- May
- Mar
- 2010
3 rounds
- Mar
- Mar
- Jan
- 2008
1 round
- Sept
- 2007
2 rounds
- Nov
- Oct
- 2004
2 rounds
- Dec
- Jan
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
Named by the firm itself, on a filing, its Form ADV or its company registration3 named
ABAdam Brian FelsenthalGeneral Counsel and Chief Compliance OfficeriForm ADV
JRJeffrey Robert JayDr. Jeffrey R. Jay is the Senior Managing Member of Great Point Partners III GP, LLC, the general partneriFiling they signed
RMRonald Marc PanzierChief Operating Officer and Chief Financial OfficeriForm ADV
We also hold 44 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
What the register says
From the firm's own filings with the SEC, which it must file accurately by law
$1.8Bassets it managesOct 2026
Registeredinvestment adviserfull reporting to the SEC
- Legal name
- Great Point Partners, LLC
- SEC number
- CRD 158423
Funds on its Form ADV
20 private funds, $1.9B in gross assets · filed Oct 2024
Private equity 18Hedge 2
- Great Point Partners IV, L.P.Private equity145 investors$535M
- Biomedical Value Fund, L.P.Hedge94 investors$516M
- Biomedical Offshore Value Fund, LTD.Hedge83 investors$336M
- Great Point Partners III, L.P.Private equity109 investors$291M
- Great Point Partners II, L.P.Private equity103 investors$66M
- Great Point Partners III-A, L.P.Private equity24 investors$51M
- GPP III - PCM, LLCPrivate equity32 investors$31M
- GPP - CF I, L.P.Private equity62 investors$30M
- GPP III - Ephicacy, LLCPrivate equity25 investors$21M
- Great Point Partners II-A, L.P.Private equity16 investors$20M
And 10 more on the filing.
Exits from the portfolio
Companies it backed that were later bought or listed5 in all
iVantage Health AnalyticsBought by The Chartis GroupUndisclosedNov 2015
Cytovance BiologicsBought by Hepalink$206MAug 2015
Solta MedicalBought by Valeant Pharmaceuticals International$250MDec 2013
Forbes Medi-TechBought by Pharmachem LaboratoriesUndisclosedAug 2010
SGX PharmaceuticalsBought by Eli Lilly$66MJul 2008
An exit counts when it came after the firm's first round in the company. From historical deal records.